Simon Gronowitz pursues new opportunities outside Biovica

Associate Professor Simon Gronowitz, founder of bio-diagnostics company Biovica, has chosen to focus on research and development of new innovations outside Biovica.
During his time in the company, both as CEO and as Director of Research, Simon Gronowitz contribution has been fundamental for the progress achieved. He is the inventor of DiviTum™, the most sensitive and precise test to measure abnormal cell division available.

DiviTum™ provides a better basis for risk assessment, prediction of therapy response and monitoring of cancer. The company has through Simons’ contribution passed a number of milestones in its successful history:

  • DiviTum™ is CE labelled, MPA registered and available in markets in EU, USA and Asia.
  • Many clinical studies have been published in many types of cancer; breast-, renal & lung
    cancer and blood malignancies.
  • Biovicas’ research has gained international recognition by winning the Network Stars Award
    for the best research project within EU, in competition with more than 300 other European

Biovica thanks Simon for his contribution over the years and wish Simon every success with his new tasks.
/ Anders Rylander, CEO Biovica

2013-05-10T11:00:33+00:00 May 10th, 2013 11:00|Regulatory|